BioClinica Inc. said John Hubbard will replace Mark Weinstein as chief executive officer of the Newtown-based company, which assists pharmaceutical manufacturers and contract research organizations in developing and managing clinical trials.

Hubbard, 58, will leave drugmaker Pfizer Inc., where he has served as senior vice president and worldwide head of development operations.

"We have a unique opportunity to partner with pharmaceutical companies and contract research organizations as they navigate unprecedented pressures, which I have experienced firsthand, and to improve the efficiency and effectiveness of drug development," Hubbard said in a statement. - David Sell